Prostate-specific antigen (PSA), a glycoprotein almost entirely secreted by the prostate gland, is considered to be one of the most reliable clinical biomarkers for the diagnosis, screening, and risk prediction of prostate cancer, and it was the first tumor biomarker approved by the Food and Drug Administration (FDA) [3, 4]. Here, KLK3 is linked to prostate carcinoma.